Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.

Detalhes bibliográficos
Autor(a) principal: Pinto, Daniel
Data de Publicação: 2011
Outros Autores: Heleno, Bruno, Gallego, Rosa, Santos, Isabel, Santiago, Luiz Miguel, Maria, Vasco
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614
Resumo: Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences.
id RCAP_7053c164cc79ffc7def5a843cb97c9c8
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/1614
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.Norma terapêutica da diabetes mellitus tipo 2: metformina uma perspectiva crítica.Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences.Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences.Ordem dos Médicos2011-04-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614oai:ojs.www.actamedicaportuguesa.com:article/1614Acta Médica Portuguesa; Vol. 24 No. 2 (2011): Março-Abril; 331-8Acta Médica Portuguesa; Vol. 24 N.º 2 (2011): Março-Abril; 331-81646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614/1196Pinto, DanielHeleno, BrunoGallego, RosaSantos, IsabelSantiago, Luiz MiguelMaria, Vascoinfo:eu-repo/semantics/openAccess2022-12-20T10:58:16Zoai:ojs.www.actamedicaportuguesa.com:article/1614Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:16.459639Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
Norma terapêutica da diabetes mellitus tipo 2: metformina uma perspectiva crítica.
title Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
spellingShingle Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
Pinto, Daniel
title_short Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
title_full Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
title_fullStr Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
title_full_unstemmed Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
title_sort Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
author Pinto, Daniel
author_facet Pinto, Daniel
Heleno, Bruno
Gallego, Rosa
Santos, Isabel
Santiago, Luiz Miguel
Maria, Vasco
author_role author
author2 Heleno, Bruno
Gallego, Rosa
Santos, Isabel
Santiago, Luiz Miguel
Maria, Vasco
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Pinto, Daniel
Heleno, Bruno
Gallego, Rosa
Santos, Isabel
Santiago, Luiz Miguel
Maria, Vasco
description Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences.
publishDate 2011
dc.date.none.fl_str_mv 2011-04-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614
oai:ojs.www.actamedicaportuguesa.com:article/1614
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/1614
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614/1196
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 24 No. 2 (2011): Março-Abril; 331-8
Acta Médica Portuguesa; Vol. 24 N.º 2 (2011): Março-Abril; 331-8
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130626075394048